Corvention’s High-Stakes Gambit to Reshape Structural Heart Procedures

FLAGSTAFF, AZ – June 24, 2026 – In a quiet procedure room in St. Louis, Missouri, a significant shift in cardiovascular medicine may have just begun. Today, Corvention, a medical device startup from Flagstaff, announced the first-ever U.S. use of its KardiaPSI™ balloon catheter, a device engineered to bring a new level of precision to a high-stakes heart procedure. The milestone case, performed by world-renowned interventional cardiologist Dr. Alan Zajarias, marks not only a clinical debut but the opening move in a carefully orchestrated market entry designed to disrupt a field dominated by industry titans.

While the successful procedure is a validation of Corvention’s technology, the deeper story lies in the company’s strategy. By targeting a fundamental challenge in structural heart interventions - the controlled treatment of heavily calcified heart valves - and coupling it with a deliberate, high-touch commercial rollout, the five-year-old company is making a calculated play for a pivotal role in the future of cardiac care.

A New Standard for an Old Problem

Balloon aortic valvuloplasty (BAV) is a critical, minimally invasive procedure for patients with severe aortic stenosis - a narrowing of the heart's aortic valve that restricts blood flow. Often used as a bridge to a more definitive treatment like a valve replacement or as a palliative option for those too frail for open-heart surgery, the procedure involves threading a catheter to the heart and inflating a balloon to crack open the stiff, calcified valve leaflets.

The challenge, however, has always been one of brute force versus finesse. Conventional balloons can struggle to deliver sufficient power consistently, and their expansion can be unpredictable against the rock-like calcium deposits common in elderly patients. This can lead to suboptimal results or complications. Corvention’s KardiaPSI™ was engineered to solve this precise problem.

Its design boasts an ultra-high pressure tolerance, capable of withstanding up to 24 atmospheres - a level of force needed to reliably fracture stubborn calcification. But power is nothing without control. The device’s differentiation lies in its precision. The balloon is “extremely non-compliant,” meaning it maintains its exact engineered shape even under immense pressure, delivering focal force precisely where needed without over-stretching surrounding tissues. It is available in an unusually granular range of sizes, from 19mm to 29mm in 1mm increments, allowing for a near-custom anatomical fit. Furthermore, its rapid inflation and deflation times are critical for minimizing the period during which the heart's output is temporarily stopped, a common technique used to stabilize the balloon during inflation.

Dr. Alan Zajarias, who performed the inaugural procedure, noted this performance directly. "The device performed exactly as anticipated, remaining very stable in place, with fast inflation/deflation times, that are critical in these complex anatomical environments," he stated. This real-world validation suggests the technology delivers on its promise of combining power with predictability.

"The successful clinical debut of the KardiaPSI balloon catheter underscores our commitment to providing interventionalists with advanced, high-performance tools designed to optimize outcomes in structural heart procedures," said Michael Franklin, CEO of Corvention, in a statement. His comment points to the company’s core mission: enhancing physician control to improve patient safety and efficacy.

A Calculated Launch into a Crowded Market

Entering the structural heart device market, a segment projected to reach nearly $29 billion by 2034, is no small feat. The space is moderately consolidated, with giants like Edwards Lifesciences, Medtronic, and Abbott holding dominant positions. Corvention, founded in 2021 and backed by a Series A funding round completed in 2024, is consciously avoiding a head-on collision.

Instead of a broad, rapid market push following its recent FDA 510(k) clearance, the company has initiated a “limited commercial launch.” This isn't a sign of limited capability but a deliberate strategy. By partnering with a select group of “elite cardiovascular centers,” Corvention is pursuing a “high-touch rollout” focused on deep collaboration, comprehensive clinical support, and flawless procedural execution. This approach allows the company to build a strong base of clinical evidence and physician advocacy, ensuring that early adopters become masters of the technology. It’s a model that prioritizes quality of use over quantity of sales, building a premium brand reputation from the ground up.

The strategy is helmed by a team with deep industry experience. CEO Michael Franklin is a veteran innovator in structural heart, while the company’s leadership and advisory board include seasoned experts in medical device development and clinical affairs. This brain trust understands that in the world of life-saving medical devices, trust is the most valuable currency.

By focusing on a specific, unsolved clinical need - predictable BAV in complex anatomies - Corvention has carved out a niche where its technological superiority can shine. While competitors offer a range of valvuloplasty catheters, KardiaPSI’s combination of high-pressure performance and precision sizing offers a compelling advantage for the most challenging cases, positioning it as an essential tool rather than just another option.

The Pioneer Perspective and Path Forward

The choice of Dr. Alan Zajarias and his St. Louis institution for the first case was itself a strategic move. A leading figure in interventional cardiology, his involvement lends immediate credibility and signals to the medical community that KardiaPSI™ is a serious technology intended for high-level clinical practice. "Being the first center in the United States to utilize the KardiaPSI technology is a testament to our program's dedication to clinical excellence and cutting-edge care," Dr. Zajarias noted, highlighting the symbiotic relationship between innovators and pioneering clinicians.

Looking ahead, Corvention plans to continue its controlled expansion, partnering with cardiovascular centers that share its commitment to procedural excellence. The goal is clear: to make KardiaPSI™ a standard and indispensable part of the structural heart toolkit, transforming what is possible in some of the most difficult patient cases.

This first procedure is more than a single data point; it is the foundation of a meticulously constructed plan. For Corvention, this high-touch, high-performance rollout is not just a launch; it is a calculated bid to become an indispensable tool in the modern catheterization lab.

Correction (June 26, 2026): A previous version of this article incorrectly stated that Corvention had established a distribution partnership with B. Braun Interventional Systems. Corvention does not have an agreement with B. Braun. This factual error has been removed, and we apologize for the inaccuracy.